Tumor tissue inhibitor of metalloproteinases-1 (TIMP-1) in hormone-independent breast cancer might originate in stromal cells, and improves stratification of prognosis together with nodal status

Experimental Cell Research

Volumn 318, Issue 10, 2012, Pages 1094-1103

  Kuvaja, P ^a,b   Hulkkonen, S ^a   Pasanen, I ^b   Soini, Y ^c   Lehtonen, S ^b   Talvensaari Mattila, A ^a   Paakko P ^a   Kaakinen, M ^b   Autio Harmainen, H ^a   Hurskainen, T ^b   Lehenkari, P ^b   Turpeenniemi Hujanen, T ^a  

^a OULU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF OULU   (Finland)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Hormone independent breast cancer; Mesenchymal stem cells; Prognosis; TIMP 1

Indexed keywords

MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER PATIENT; CELL LYSATE; CELL TYPE; CONTROLLED STUDY; CYTOPLASM; FEMALE; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MESENCHYMAL STEM CELL; PRIORITY JOURNAL; PROGNOSIS; STROMA CELL;

EID: 84860365022     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2012.03.009     Document Type: Article

References (40)

1. Schrohl A.S., Holten-Andersen M.N., Peters H.A., Look M.P., Meijer-van Gelder M.E., Klijn J.G., Brunner N., Foekens J.A. Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer. Clin. Cancer Res. 2004, 10:2289-2298.
2. Talvensaari-Mattila A., Turpeenniemi-Hujanen T. High preoperative serum TIMP-1 is a prognostic factor for survival in breast carcinoma. Breast Cancer Res. Treat. 2005, 89:29-34.
3. Kuvaja P., Talvensaari-Mattila A., Turpeenniemi-Hujanen T. High preoperative plasma TIMP-1 is prognostic for early relapse in primary breast carcinoma. Int. J. Cancer 2008, 123:846-851.
4. Würtz S.Ø., Møller S., Mouridsen H., Hertel P.B., Friis E., Brünner N. Plasma and serum levels of tissue inhibitor of metalloproteinases-1 are associated with prognosis in node-negative breast cancer: a prospective study. Mol. Cell. Proteomics 2008, 7:424-430.
5. Hayakawa T., Yamashita K., Tanzawa K., Ujichima E., Iwata K. Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett. 1992, 298:29-32.
6. Sternlicht M.D., Werb Z. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol. 2001, 17:463-516.
7. Würtz S.Ø., Schrohl A.S., Mouridsen H., Brünner N. TIMP-1 as a tumor marker in breast cancer-an update. Acta Oncol. 2008, 47:580-590.
8. Turpeenniemi-Hujanen T. Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie 2005, 87:287-297.
9. Nakopoulou L., Giannopoulou I., Stefanaki K., Panayotopoulou E., Tsirmpa I., Alexandrou P., Mavrommatis J., Katsarou S., Davaris P. Enhanced mRNA expression of tissue inhibitors of metalloproteinase-1 (TIMP-1) in breast carcinomas is correlated with adverse prognosis. J. Pathol. 2002, 197:307-313.
10. Kuvaja P., Talvensaari-Mattila A., Pääkkö P., Turpeenniemi-Hujanen T. The absence of immunoreactivity for tissue inhibitor of metalloproteinase-1 (TIMP-1), but not for TIMP-2, protein is associated with a favorable prognosis in aggressive breast carcinoma. Oncology 2005, 68:196-203.
11. Studeny M., Marini F.C., Champlin R.E., Zompetta C., Fidler I.J., Andreeff M. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res. 2002, 62:3603-3608.
12. Karnoub A.E., Dash A.B., Vo A.P., Sullivan A., Brooks M.W., Bell G.W., Richardson A.L., Polyak K., Tubo R., Weinberg R.A. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007, 449:557-565.
13. Kidd S., Spaeth E., Dembinski J.L., Dietrich M., Watson K., Klopp A., Battula V.L., Weil M., Andreeff M., Marini F.C. Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells 2009, 27:2614-2623.
14. DeWever O., Demetter P., Mareell M., Bracke M. Stromal myofibroblasts are drivers of invasive cancer growth. Int. J. Cancer 2008, 123:2229-2238.
15. Spaeth E.L., Dembinski J.L., Sasser A.K., Watson K., Klopp A., Hall B., Andreeff M., Marini F. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One 2009, 4:e4992.
16. Goldhirsch A., Glick J.H., Gleber R.D., Coates A.S., Thurlimann B., Senn H.J. Panel members, meeting highlights: international expert consensus on the primary therapy of early breast cancer. Ann. Oncol. 2005, 16:1569-1583.
17. Fulford L.G., Easton D.F., Reis-Filho J.S., Sofronis A., Gillett C.E., Lakhani S.R., Hanby A. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology 2006, 49:22-34.
18. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F.C., Krause D.S., Deans R.J., Keating A., Prockop D.J., Horwitz E.M. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy, position statement. Cytotherapy 2006, 8:315-317.
19. Leskelä H.-V., Risteli J., Niskanen S., Koivunen J., Ivaska K.K., Lehenkari P. Osteoblast recruitment from stem cells does not decrease by age at late adulthood. Biochem. Biophys. Res. Commun. 2003, 311:1008-1013.
20. Livak K.J., Schmittigen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408.
21. Hurskainen T., Höyhtyä M., Tuuttila A., Oikarinen A., Autio-Harmainen H. mRNA expressions of TIMP-1, -2, and -3 and 92kD type IV collagenase in early human placenta and decidual membrane as studied by in situ hybridization. J. Histochem. Cytochem. 1996, 44:1379-1388.
22. Määttä M., Heljasvaara R., Sormunen R., Pihlajaniemi T., Autio-Harmainen H., Tervo T. Differential expression of collagen types XVIII/endostatin and XV in normal, keratoconus, and scarred human corneas. Cornea 2006, 25:341-349.
23. Ries C., Egea V., Karow M., Kolb H., Jochum M., Neth P. MMP-2, MT1-MMP, and TIMP-2 are essential for the invasive capacity of human mesenchymal stem cells: differential regulation by inflammatory cytokines. Blood 2007, 109:4055-4063.
24. Wu Z.S., Wu Q., Yang J.H., Wang H.Q., Ding X.D., Yang F., Xu X.C. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int. J. Cancer 2008, 122:2050-2056.
25. Figueira R.C., Gomes L.R., Neto J.S., Silva F.C., Silva I.D., Sogayar M.C. Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential. BMC Cancer 2009, 9:e20.
26. Holten-Andersen M.N., Hansen U., Brünner N., Nielsen H.J., Illemann M., Nielsen B.S. Localization of tissue inhibitor of metalloproteinases 1 (TIMP-1) in human colorectal adenoma and adenocarcinoma. Int. J. Cancer 2005, 113:198-206.
27. Usher P.A., Sieuwerts A.M., Bartels A., Lademann U., Nielsen H.J., Holten-Andersen L., Foekens J.A., Brünner N., Offenberg H. Identification of alternatively spliced TIMP-1 mRNA in cancer cell lines and colon cancer tissue. Mol. Oncol. 2007, 1:205-215.
28. García M.F., González-Reyes S., González L.O., Junquera S., Berdize N., Del Casar J.M., Medina M., Vizoso F.J. Comparative study of the expression of metalloproteases and their inhibitors in different localizations within primary tumours and in metastatic lymph nodes of breast cancer. Int. J. Exp. Pathol. 2010, 91:324-334.
29. Yoshiji H., Gomez D.E., Thorgeisson U.P. Enhanced RNA expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in human breast cancer. Int. J. Cancer 1996, 69:131-134.
30. Jung K.K., Liu X.W., Chirco R., Fridman R., Kim H.R. Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein. EMBO J. 2006, 25:3934-3942.
31. Pols M.S., Klumperman J. Trafficking and function of the tetraspanin CD63. Exp. Cell Res. 2009, 315:1584-1592.
32. LaFleur L.A., Daosong X., Hemler M.E. Tetraspanin proteins regulate membrane type-1 matrix metalloproteinase-dependent pericellular proteolysis. Mol. Biol. Cell 2009, 20:2030-2040.
33. Ritter L.M., Garfield S.H., Thorgeirsson U.P. Tissue inhibitor of metalloproteinases-1 (TIMP-1) binds to the cell surface and translocates to the nucleus of human MCF-7 breast carcinoma cells. Biochem. Biophys. Res. Commun. 1999, 257:494-499.
34. Bigelow R.L., Williams B.J., Carroll J.L., Daves L.K., Cardelli J.A. TIMP-1 overexpression promotes tumorigenesis of MDA-MB-231 breast cancer cells and alters expression of a subset of cancer promoting genes in vivo distinct from those observed in vitro. Breast Cancer Res. Treat. 2009, 117:31-44.
35. McCarthy K., Maguire T., McGreal G., McDermott E., O'Higgins N., Duffy M.J. High levels of tissue inhibitors of metalloproteinase-1 predict poor outcome in patients with breast cancer. Int. J. Cancer 1999, 884:44-48.
36. Brummer O., Athar S., Riethdorf L., Löning T., Hebst H. Matrix-metalloproteinases 1, 2 and 3 and their tissue inhibitors 1 and 2 in benign and malignant breast lesions: an in situ hybridization study. Virchows Arch. 1999, 435:566-573.
37. Ree A.H., Florenes V.A., Berg J.P., Maelandsmo G.M., Nesland J.M., Fostad O. High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases. Clin. Cancer Res. 1997, 3:1623-1628.
38. Span P.N., Lindberg R.L., Manders P., Tjan-Heijnen V.C., Heuvel J.J., Beex L.V., Sweep C.G. Tissue inhibitors of metalloproteinase expression in human breast cancer: TIMP-3 is associated with adjuvant endocrine therapy success. J. Pathol. 2004, 202:395-402.
39. Inoue H., Mimori K., Shiraishi T., Kataoka A., Sadanaga N., Ueo H., Barnard G.F., Mori M. Expression of tissue inhibitor of matrix metalloproteinase-1 in human breast carcinoma. Oncol. Rep. 2000, 7:871-874.
40. Nakopoulou L., Giannopoulou I., Lazaris A.Ch., Alexandrou P., Tsirmpa I., Markaki S., Panayotopoulou E., Keramopoulos A. The favorable prognostic impact of tissue inhibitor of matrix metalloproteinases-1 protein overexpression in breast cancer cells. APMIS 2003, 111:1027-1036.